Progressive Osteolysis After Use of Synthetic Bone Graft Substitute

Punnavit Harimtepathip 1, Lamar F. Callaway 1, Margaret A. Sinkler 2, Suash Sharma 3, Kelly C. Homlar 1

1. Orthopedic Surgery, Augusta University Medical College of Georgia, Augusta, USA. 2. Medicine, Augusta University Medical College of Georgia, Augusta, USA. 3. Hematology and Oncology, Augusta University Medical College of Georgia, Augusta, USA.

Corresponding author: Punnavit Harimtepathip, punnavit13@gmail.com

Abstract

Benign bone tumors are commonly treated with intralesional curettage and bone graft, with autogenous bone graft being the gold standard. However, autogenous bone graft has its limitation, and artificial bone graft substitutes were developed as an alternative. PRO-DENSE™ (Wright Medical Technology, Arlington, Tennessee) is a calcium sulfate and calcium phosphate mixed bone graft substitute that is biodegradable and osteoconductive, which has made them a popular choice among surgeons. However, long-term studies of this treatment method for benign tumors are still limited.

In this report, we present a case of progressive femoral neck osteolysis caused by an inflammatory reaction to PRO-DENSE™ two years after intralesional curettage and bone grafting of a benign bone tumor.

A twenty-one-year-old female with fibrous dysplasia underwent intralesional curettage with the use of PRO-DENSE™ bone substitute to fill the cavitary defect. She developed an inflammatory reaction to the bone graft substitute leading to increasing pain and osteolysis requiring a reoperation.

Bone graft substitute has many advantages; however, they should be used with discretion due to many unknowns regarding their safety and long-term outcomes.

Introduction

Benign bone tumors are commonly treated with intralesional curettage. Although controversy exists with regards to the augmentation of the remaining osseous defect, bone grafting remains a reasonable option [1-3]. The gold standard for all grafting procedures is autogenous bone graft; however, due to limited supply and donor site morbidity, artificial bone graft substitutes were developed as an alternative [4]. One synthetic bone graft substitute is PRO-DENSE™ (Wright Medical Technology, Arlington, Tennessee), which is composed of calcium sulfate and calcium phosphate matrix mixed with beta-tricalcium phosphate granules [5]. PRO-DENSE™ and similar bone graft substitutes have advantages of being abundant in supply, biodegradable, and osteoconductive, which has made them a popular choice among surgeons. However, long-term studies of this treatment method for benign tumors are still limited. Despite advances in bone graft substitute composition, complications directly related to implanted synthetic bone graft continue to occur, many of which are related to local inflammatory reactions [6-8].

In this report, we present a case of progressive femoral neck osteolysis caused by an inflammatory reaction to PRO-DENSE™, two years after intralesional curettage and bone grafting of a benign bone tumor. The patients and/or their families were informed that data from the case would be submitted for publication and gave their consent.

Case Presentation

A twenty-one-year-old female with no significant past medical history presented to the clinic with a three-year-history of left groin pain made worse with weight-bearing. Initial radiographs showed an approximately four-centimeter lesion within inferomedial femoral neck, surrounded by a reactive sclerotic border. MRI showed an isolated lesion with distinct margins within the femoral neck, which was isointense T1, hyperintense on T2 with some internal mineralized areas and reactive sclerotic border, a large amount of surrounding edema in proximal diaphysis up to the physis, suggestive of maturing fibro-osseous lesion/fibrous dysplasia (Figures 1 and 2). Despite extensive conservative treatment, she continued to have pain with weight-bearing to the point it was limiting normal daily activities. An image-guided core needle biopsy was performed and was consistent with fibrous dysplasia. Given her persistent pain, she was taken for open biopsy, intralesional curettage, and prophylactic stabilization of the left femoral neck with a dynamic...
hip screw. Twenty cubic centimeters of PRO-DENSE™ were placed within the osseous defect (Figure 3).

FIGURE 1: Radiographic anteroposterior (A) and frog-leg lateral (B) views of the hip from initial presentation revealed lesion within the left femoral neck

FIGURE 2: MRI scan of the left hip

MRI scan of the left hip with T2-weighted coronal image (A) demonstrating a hyperintense isolated lesion with distinct sclerotic margins and surrounding bone marrow edema within the femoral neck and a T1-weighted coronal image (B) showing an isointense lesion with sclerotic margins
FIGURE 3: Radiographic anteroposterior (A) and lateral (B) views of the left hip intraoperatively after curettage with use of PRO-DENSE™ and operative fixation.

The patient did well initially but began having increasing pain. Serial radiographs showed expected centripetal resorption of the graft, all of which was resorbed by five months; however, the patient continued to have progressive osteolysis two years postoperatively (Figure 4). Given the extent of osteolysis and disruption of the anterior cortex, she was referred for an image-guided core needle biopsy to confirm the original diagnosis and that no secondary lesion was present. Biopsy showed a hypocellular specimen with few macrophages, which was negative for malignancy with negative cultures. An inflammatory reaction to the bone graft substitute was suspected, and open biopsy via an anterior approach to the hip, intralesional curettage, and placement of polymethylmethacrylate (PMMA) bone cement was performed. Intraoperative biopsy showed fragments of fibro-connective stroma and remodeled bone with chronic inflammation, hemosiderin, scar fibrosis, and foreign-body giant cell reaction (Figure 5). Special stains for bacteria, acid-fast bacillus (AFB), and fungal organisms were negative, with no malignancy or residual fibrous dysplasia identified. Post-operative images from the curettage and PMMA placement were obtained (Figure 6).

Following the second procedure, the patient progressed as expected. She had significant improvement in pain and was able to return to all previous activities. Radiographs at one-year follow-up from her second operation revealed stable implants with no evidence of progressive osteolysis (Figure 7).
FIGURE 4: Radiographic anteroposterior (A) and frog-leg lateral (B) views of the left hip reveal progressive osteolysis within the femoral neck in the area of previous bone graft placement.
FIGURE 5: Hematoxylin and eosin staining at 200 magnification showing a large deposit of foreign material with associated foreign-body type giant cell reaction and surrounding chronic inflammation.
FIGURE 6: Postoperative radiographic anteroposterior (A) and frog-leg lateral (B) views of the left hip after curettage and PMMA placement

PMMA - polymethylmethacrylate

FIGURE 7: Radiographic anteroposterior (A) and frog-leg lateral (B) views of the left hip taken at one-year follow up reveal no areas of osteolysis

Discussion

Following intralesional curettage of benign bone tumors, bone graft is often used to fill the osseous defect in an attempt to accelerate bony ingrowth and allow for possible earlier weight-bearing [9]. While autograft is historically the gold standard for bone substitution, bone graft extenders and substitutes are abundant in supply, readily available, and avoid complications from the use of autograft or allograft, such as donor site
Conclusions

In conclusion, bone graft substitutes have many advantages, including decreased donor site morbidity, cost, and availability. However, there are many unknowns about their safety, efficacy, and long-term outcomes. Bone graft substitutes are viable alternatives to autograft and allografts; however, they should be used with discretion. Our case report represents a clinically significant osteolytic reaction to bone graft substitute causing progressive osteolysis. Histologic evaluation of the intra-operative specimen revealed histiocyte rich chronic inflammation and a few giant cells with both polarizable and nonpolarizable foreign material which we believe was a reaction to the ceramic bone graft substitute, PRO-DENSE™, used in the initial procedure. In our case, this inflammatory reaction to the bone graft substitute led to an increased area of osteolysis around the implant in the femoral neck region, as seen in the postoperative radiograph. This leads to weakening of the osseous integrity and increases the risk for serious complications such as implant loosening, femoral neck fracture, avascular necrosis, and collapse of the articular surface which may necessitate the need for arthroplasty in a young patient.

An additional shortcoming of synthetic bone graft substitutes is the graft incorporation profile. Many of these products contain calcium sulfate which is absorbed before bony ingrowth occurs. The radiolucency observed on postoperative radiographs can be difficult to interpret as recurrence or normal resorption. There is typically a predictable pattern of absorption and osseous ingrowth, which progresses from the periphery towards the center [13,14]. Austen et al. discusses unexpected radiographic lucency (URLs) following the use of calcium sulfate/tricalcium phosphate bone graft substitutes [9]. They describe URLs as any radiolucency that varied from the typical pattern of osseous ingrowth and occurred in 13% of patients in their study. The average time to identification of the URL was 27 weeks. They were unable to identify the specific etiology but proposed URLs could be related to inflammatory or foreign body reactions and ultimately concluded that URLs do not result in clinically relevant adverse events [9]. In our case, we initially noticed a URL at three months postoperatively, but unlike URLs previously described, this radiolucency continued to enlarge two years postoperatively (Figure 4), causing significant pain and increasing the risk of serious complication, ultimately led to an additional operation two years after the initial procedure.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS: Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am. 1999, 81:811-20.
2. Sethmann I, Luft C, Kleebe HJ: Development of phosphatized calcium carbonate biomaterials as bioactive bone graft substitute materials, part I: incorporation of magnesium and strontium ions. J Funct Biomater. 2018, 9:69. 10.3390/jfb9040069
3. Rolvien T, Barbeck M, Wenisch S, Amling M, Krause M: Cellular mechanisms responsible for success and failure of bone substitute materials. Int J Mol Sci. 2018, 19:2893. 10.3390/ijms19102893
4. Gazdag AR, Lane JM, Glaeser D, Forster RA: Alternatives to autogenous bone graft: efficacy and indications. J Am Acad Orthop Surg. 1995, 5:1-8.
5. Urban RM, Turner TM, Hall DJ, Joune N, Gitelis S: Increased bone formation using calcium sulfate-calcium phosphate composite graft. Clin Orthop Relat Res. 2007, 459:110-7. 10.1097/BLO.0b013e3180596902
6. Robinson D, Alk D, Sandbank J, Farber R, Halperin N: Inflammatory reactions associated with a calcium sulfate bone substitute. Ann Transplant. 1999, 4:3-4.
7. Kelly CM, Wilkins R, Gitelis S, Hartjen C, Watson JT, Kim PT: The use of a surgical grade calcium sulfate as a bone graft substitute: results of a multicenter trial. Clin Orthop Relat Res. 2001, 328:42-50.
8. Beurerlein MJ, McKee MD: Calcium sulfates: what is the evidence? J Orthop Trauma. 2010, 24:46-51. 10.1097/BOT.0b013e3181cec48e
9. Friesenbichler J, Maurer-Ertl W, Sadoghi P, Pirker-Fruehauf U, Bodo K, Leithner A: Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX®. Clin Orthop Relat Res. 2014, 472:976-82. 10.1007/s11999-015-3505-z
10. Civinini R, Capone A, Carulli C, Matassi F, Nistri L, Innocenti M: The kinetics of remodeling of a calcium sulfate/calcium phosphate bioerodable. J Mater Sci Mater Med. 2017, 28:157. 10.1007/s10856-017-9940-5
11. Kotrais NA, Parasu N, Finlay K, Jurriaans E, Ghert M: Chronology of the radiographic appearances of the calcium sulfate-calcium phosphate synthetic bone graft composite following resection of bone tumours: a preliminary study of the normal post-operative appearances. Skeletal Radiol. 2011, 40:563-70. 10.1007/s00251-010-1057-7
12. Tan V, Evaniew N, Finlay K, Jurriaans E, Ghert M, Deheshi B, Parasu N: Chronology of the radiographic appearances of the calcium sulfate-calcium phosphate synthetic bone graft composite following resection of bone tumours: a follow-up study of postoperative appearances. Can Assoc Radiol J. 2016, 67:21-7. 10.1016/j.carj.2014.11.004